SSShailee Shah

Shailee Shah

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shailee Shah has a total of 110 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Teaching NeuroImage: Opioid-Associated Amnestic Syndrome

    by Patricia Ines Mendoza Zulueta, Hannah Kim, Shailee Shah

  • Immunotherapy in Patients With Small-Cell Lung Cancer and Lambert-Eaton Myasthenic Syndrome: A Multi-institutional Case Series

    by Kübra Canaslan, Ditte Primdahl, Wade Iams, Cassidi Lugo, Karan Dixit, Hafeez Chatoor, Ticiana Leal, Shailee Shah

  • Teaching NeuroImages: Trident Sign in GFAP-Associated Meningoencephalomyelitis

    by Nicholas S. Mallett, Meryim Poursheykhi, Shailee Shah, James Eaton

  • Open Access

    Case Report: Dynamic Fusiform MCA Aneurysm in Culture‐Negative Endocarditis and DRESS Syndrome: Infectious Aneurysm or Superimposed Immuno‐Inflammatory Arteriopathy?

    by Ahmed Asif, Maya C. Shadid, Muhammad Dhanani, Shailee S. Shah, Kristin Miller, William Metcalf‐Doetsch, Donald R. Cantrell, Sameer A. Ansari

    A 37‐year‐old woman with reported beta‐thalassemia minor presented with right Sylvian subarachnoid hemorrhage after several weeks of fever of unknown origin while receiving antibiotic therapy. Initial catheter angiography demonstrated right middle cerebral artery (MCA) branch occlusion without aneurysm; repeat imaging 1 week later demonstrated a dynamic distal right MCA fusiform aneurysm with circumferential vessel wall enhancement and adjacent cerebritis. Echocardiography revealed aortic valve vegetation, but blood cultures, plasma microbial cell‐free DNA testing, and CSF metagenomics were negative throughout her hospitalization. The cerebral aneurysm was managed as a culture‐negative infectious aneurysm, but parent vessel sacrifice was deferred because functional MRI demonstrated bihemispheric language representation and there was a pre‐existing adjacent MCA branch occlusion. Her course was complicated by DRESS syndrome (suspected culprit: vancomycin), accompanied by cervical lymph node histiocytic necrotizing lymphadenitis with Kikuchi‐Fujimoto‐disease‐like features, prompting immunosuppression. Following DRESS‐directed corticosteroid therapy, follow‐up brain MRI and MR angiography (MRA) showed inflammatory changes and aneurysm remodeling and improvement in adjacent cerebral edema. This case illustrates the diagnostic and management overlap between culture‐negative infectious arteritis and a possible superimposed immuno‐inflammatory arteriopathy in the setting of DRESS‐associated hyperinflammation, highlighting the need for serial brain MRI and MRA, MR vessel‐wall imaging, and multidisciplinary decision‐making.

  • Neurofilament light chain levels differentiate ischemic from inflammatory optic neuropathies

    by Shailee Shah, Sara Mariotto, Eoin P. Flanagan, Sean J. Pittock, Elia Sechi, M. Tariq Bhatti, John J. Chen


  • Outcomes After Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

    by Smathorn Thakolwiboon, Vyanka Redenbaugh, Bo Chen, Sage Hewitt, Shailee Shah, Itay Lotan, Michael Levy, Mirasol Forcadela, Saif Huda, Julie Pique, et al.

    Data on the plasma exchange (PLEX) in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are limited. Herein, we evaluate outcomes after PLEX in MOGAD. This international multicenter retrospective cohort study included patients from 18 tertiary care centers in 6 countries. Inclusion criteria included fulfillment of the 2023 International MOGAD panel criteria, receipt of at least 3 sessions of PLEX, and follow-up of ≥3 months after PLEX. Patients with coexisting neuroinflammatory disorders were excluded. We assessed the frequency of complete recovery (CR), clinically significant improvement (CSI), visual acuity (VA), and Expanded Disability Status Scale (EDSS). Logistic regression analyses were performed to identify predictors of CR and CSI. Of 234 patients, 135 (58%) were female. The median (interquartile range [IQR]) age at attack was 34 (IQR 22-49) years, and 42 (17%) were children. In 165 of 243 (68%), the attack treated with PLEX was the first attack. Attack phenotypes included 161 optic neuritis (235 eyes), 77 myelitis, 24 acute disseminated encephalomyelitis, 15 brainstem/cerebellar, 3 cerebral-cortical encephalitis attack, and 1 cerebral polyfocal deficit-36 with >1 core phenotypes. A total of 239 (99%) attacks were also treated with corticosteroids and 32 (13%) with IV immunoglobulins. VA in optic neuritis improved from 20/400 (20/70-hand motion) to 20/20 (20/20-20/30), p < 0.001, and EDSS decreased from a median of 4.0 (3.0-6.5) to 1.0 (0.0-2.5), p < 0.001. Of 229 attacks without subsequent attacks within 3 months, 100 (44%) achieved CR and 213 (93%) CSI. The probability of CR was decreased with advanced age (adjusted odd ratio [95% CI] 0.97 [0.96-0.99] per year), higher EDSS worsening from baseline (0.66 [0.54-0.81] per 0.5 increment) and delayed PLEX (0.98 [0.96-0.99] per day). Advanced age (0.97 [0.96-0.99] per year) and delayed PLEX (0.95 [0.94-0.96] per day) decreased the probability of CSI. We observed favorable outcomes after PLEX in MOGAD attacks. However, advanced age and delayed initiation of PLEX were associated with a reduced probability of improvement. The absence of a control group limits our ability to differentiate PLEX effects from spontaneous recovery, prior corticosteroid response, or long-term immunotherapy. Future prospective studies are needed to assess the impact of PLEX on improvement. This study provides Class IV evidence that PLEX is associated with favorable clinical outcomes in patients with MOGAD.


  • Open Access

    Parasagittal dural space and arachnoid granulations morphology in pre-clinical and early clinical multiple sclerosis

    by Ahmad Toubasi, Kilian Hett, Junzhong Xu, Caroline Gheen, Taegan Vinarsky, Chloe Cho, James E Eaton, Shailee Shah, Colin McKnight, Richard D Dortch, et al.

    Background: There is limited knowledge on the post-glymphatic structures such as the parasagittal dural (PSD) space and the arachnoid granulations (AGs) in multiple sclerosis (MS). Objectives: To evaluate differences in volume and macromolecular content of PSD and AG between people with newly diagnosed MS (pwMS), clinically isolated syndrome (pwCIS), or radiologically isolated syndrome (pwRIS) and healthy controls (HCs) and their associations with clinical and radiological disease measures. Methods: A total of 69 pwMS, pwCIS, pwRIS, and HCs underwent a 3.0 Tesla magnetic resonance imaging (MRI) including selective inversion recovery quantitative magnetization transfer imaging to compute the macromolecular-to-free water pool-size-ratio (PSR) and the free water relaxation rate (R 1f ), T 2 -weighted (T 2 -w) volumetric isotropic turbo-spin-echo to segment the PSD and AG, T 2 -w fluid-attenuated inversion recovery images to compute T 2 -lesions burden, and a T 1 -w sequence to quantify chronic black holes (cBHs) burden and brain parenchymal fraction. Results: After adjusting for age and sex, larger frontal ( p = 0.006) and parietal ( p = 0.047) PSD volumes along with larger parietal AG volumes ( p = 0.033) were measured in patients compared to HCs. Parietal PSD volume correlated with cBH PSR ( r = −0.430, p = 0.032). Conclusion: Upon diagnosis, enlarged structures in the post-glymphatic system may be observed, indicating a need for further investigation of their role.


  • Open Access

    Comprehensive Analysis of Paraneoplastic Neurologic Syndrome and PNS-CARE Diagnostic Criteria in Clinical Practice

    by Hannah Zhao-Fleming, Mohamed Rezk, Shailee Shah, Pranjal Gupta, Anastasia Zekeridou, Eoin P. Flanagan, Sean J. Pittock, Andrew McKeon, Divyanshu Dubey

    Paraneoplastic neurologic syndrome (PNS) diagnostic criteria were first proposed in 2004 and updated in 2021. The PNS-CARE score, derived from the updated criteria, is a composite model for assigning likelihood for patients with suspected PNS. In this study, we evaluated the utility and applicability of the 2021 PNS-CARE score and present our PNS cohort. This is a retrospective study. We identified Mayo Clinic patients suspected to have PNS (1/2005-12/2020) and collected relevant information including demographics, PNS presentation, and clinical outcomes. Inclusion criteria were the following: (1) patients with a syndrome consistent with PNS and (2) patients with sufficient information available in charts. Exclusion criteria were the following: (1) evaluation only before 2005, (2) patients not evaluated by neurology, (3) presentation after immune checkpoint inhibitors, and (4) syndromes not included in 2021 criteria. All patients were evaluated for the 2021 and 2004 PNS criteria. We identified 484 patients suspected to have PNS at initial presentation, of whom 212 (44%) were considered to have PNS after completion of evaluation. Among these 212 patients, the most common autoantibodies were PCA1 (Yo)-IgG (17%), KLHL11-IgG (16%), and CRMP5-IgG (14%) and the most common phenotypes were rapidly progressive cerebellar syndrome (29%), brainstem encephalitis (14%), and limbic encephalitis (8%). The 2021 PNS criteria definite/probable categorization (PNS-CARE score ≥ 6) had a sensitivity and specificity of 93% and 100%, respectively, while the 2004 PNS criteria definite categorization had a sensitivity and specificity of 67% and 99%, respectively. We found 15 patients with a PNS-CARE score ≤5 who likely had PNS on our review. The most common presentation among these patients was KLHL11-IgG brainstem encephalitis (7/15, 47%) with likely burned-out testicular tumor. Our study validates the PNS-CARE score. A clearer understanding of typical PNS presentation and common underlying malignancies and autoantibodies can aid in earlier and more accurate diagnosis, which is crucial for downstream clinical decisions. Some patients with an intermediate-risk phenotype do not meet probable/definite criteria despite the presence of high-risk antibodies and/or underlying malignancy.


  • Open Access

    Frequency of Asymptomatic Optic Nerve Enhancement in 203 Patients With MOG Antibody-Associated Disease

    by Deena Tajfirouz, Ajay Madhavan, Johann M. Pacheco Marrero, Karl N. Krecke, Kalli J. Fautsch, Eoin P. Flanagan, Sean J. Pittock, Shailee Shah, M. Tariq Bhatti, John J. Chen

    Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a distinct CNS demyelinating disease. The rate of asymptomatic optic nerve enhancement on MRI has not been explored in patients with MOGAD. An improved understanding of this would guide clinical practice and assessment of treatment efficacy. We aimed to determine the frequency of asymptomatic optic nerve enhancement in MOGAD. This was a retrospective review of patients evaluated at Mayo Clinic with MOGAD between January 1, 2000, and August 1, 2021 (median follow-up 1.6 [range 1-19] years). MRI studies were reviewed by masked neuroradiologists. Scans performed within 30 days of ON attack were classified as attack scans. Images obtained for routine surveillance, before ON attack, or at the time of non-ON attack were classified as interattack scans. Five hundred sixty-six MRIs (203 unique patients, 53% female) were included. Interattack MRIs represented 341 (60%) of the scans (median 36 days post-ON [range -1,032 to 6,001]). Of the interattack scans, 43 of 341 (13%), 30 unique patients, showed optic nerve enhancement. The enhancement was located at prior sites of ON in 35 of 43 (81%). Among the 8 patients with enhancement in new optic nerve areas, 6 had acute disseminated encephalomyelitis without an eye examination at the time of the MRI and 2 had preceding ON without imaging. Long-term visual outcomes showed no significant difference between those with and without asymptomatic enhancement, with improved visual acuity in most patients. Asymptomatic optic nerve enhancement occurred in 13% of interattack MRIs, the majority in patients with prior ON and occurring at prior sites of optic nerve enhancement. New asymptomatic optic nerve enhancement in areas without prior ON was rare. These findings are important for understanding the natural history of MOGAD, the interpretation of symptoms or response to treatment, and the adjudication of attacks in clinical trials.